Greywolf Therapeutics Announces Clinical Supply Agreement with Regeneron for Trial Evaluating GRWD5769 in Combination with Libtayo® (cemiplimab)

Greywolf Therapeutics closes oversubscribed $49 Million Series B financing to advance first-of-its-kind neoantigen creation approaches.

Greywolf has developed and is advancing a unique immune-oncology therapeutic strategy utilizing a proprietary antigen modulation strategy to reveal novel and potent cancer antigens on the surface of tumour cells.

Greywolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

We are proud to announce our advancement of GRWD5769 into the clinic as this reflects a critical first step in our evaluation of this first-in-class ERAP1 inhibitor.